Bydureon

Physical Activity, Type 2 Diabetes, Diet
Treatment
20 Active Studies for Bydureon

What is Bydureon

ExenatideThe Generic name of this drug
Treatment SummaryExenatide is a medication that helps to control blood sugar levels. It works by activating a receptor in the body that increases insulin production, decreases the amount of glucagon in the body, and slows down the emptying of the stomach. Exenatide was approved by the FDA in 2005 and is prescribed to people with diabetes.
Byettais the brand name
image of different drug pills on a surface
Bydureon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Byetta
Exenatide
2005
10

Effectiveness

How Bydureon Affects PatientsExenatide helps to regulate the body's response to glucose, releasing more insulin and less glucagon when it is needed. This helps to prevent dangerously high or low blood sugar levels. It also slows down how quickly the stomach empties, meaning that the glucose enters the body's system more slowly. This further helps to prevent dangerous spikes or drops in blood sugar levels.
How Bydureon works in the bodyExenatide is a drug that helps control blood sugar levels. It works by activating a receptor in the body that stimulates insulin production, while reducing glucagon production. It also slows down digestion and reduces food intake, helping to prevent episodes of high or low blood sugar.

When to interrupt dosage

The measure of Bydureon is contingent upon the identified affliction. The amount of dosage fluctuates as per the technique of administration cited in the table beneath.
Condition
Dosage
Administration
Physical Activity
, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous
Type 2 Diabetes
, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous
Diet
, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Subcutaneous, Solution, Solution - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Injection, suspension, extended release, Injection, suspension, extended release - Subcutaneous, Suspension, extended release, Suspension, extended release - Subcutaneous

Warnings

Bydureon Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Exenatide may interact with Pulse Frequency
There are 20 known major drug interactions with Bydureon.
Common Bydureon Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Moderate
Exenatide can cause an increase in the absorption of (R)-warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.
(S)-Warfarin
Moderate
Exenatide can cause an increase in the absorption of (S)-Warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.
2,4-thiazolidinedione
Moderate
The risk or severity of hypoglycemia can be increased when Exenatide is combined with 2,4-thiazolidinedione.
4-hydroxycoumarin
Moderate
Exenatide can cause an increase in the absorption of 4-hydroxycoumarin resulting in an increased serum concentration and potentially a worsening of adverse effects.
AICA ribonucleotide
Moderate
The risk or severity of hypoglycemia can be increased when Exenatide is combined with AICA ribonucleotide.
Bydureon Toxicity & Overdose RiskAnimal studies have linked exenatide to birth defects in the rib cage and spine, as well as slowed growth. Uncontrolled high blood sugar can increase the risk of miscarriage in humans by up to 25%. There are no human studies on the effects of exenatide during pregnancy, so the drug should only be taken if the benefits outweigh the risks. Exenatide is found in mouse milk at a concentration of 2.5% of the plasma, though this may not apply to humans. There is also no data on its effects on breastfed infants. Exenatide is not recommended for pediatric or geriatric patients.
image of a doctor in a lab doing drug, clinical research

Bydureon Novel Uses: Which Conditions Have a Clinical Trial Featuring Bydureon?

162 active studies are actively evaluating the utility of Bydureon in the management of Type 2 Diabetes.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
166 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Bydureon Reviews: What are patients saying about Bydureon?

5Patient Review
2/16/2018
Bydureon for Additional Medication for Diabetes Type 2
I've only been taking this medication for a short while, but I have already seen some results. My appetite has increased and my blood sugar is more stable. I also experienced headaches at first, but they went away after a few days.
5Patient Review
9/14/2018
Bydureon for Type 2 Diabetes Mellitus
I've been on this medication for around four months and it has helped me lose 33 pounds gradually, which is exactly what I needed. My blood sugar levels are now more consistent and I haven't had any major issues with nausea or hunger. This has been a great experience overall.
5Patient Review
4/27/2019
Bydureon for Additional Medication for Diabetes Type 2
I've been really pleased with how this medication has worked. My blood sugar levels have decreased so much that I barely need any insulin now. The only downside is that my appetite is suppressed and I've lost some weight, but I'll take those results any day!
5Patient Review
9/14/2018
Bydureon for Type 2 Diabetes Mellitus
This medication has helped me lose a significant amount of weight. I've been on it for 4 months and have lost 33 pounds (7 per month, on average). My blood sugar is now more consistent, and I've had to reduce my intake of other medications as a result. The only downside is that I sometimes experience nausea, but it's manageable with medication.
5Patient Review
4/27/2019
Bydureon for Additional Medication for Diabetes Type 2
So far, I've been really pleased with how this medication has worked. My blood sugar has decreased to the point where I barely need any insulin at all. The only downside is that my appetite is suppressed and I've lost some weight, but those are pretty minor complaints in comparison to the benefits.
5Patient Review
12/15/2017
Bydureon for Type 2 Diabetes Mellitus
Though there was some oozing and a lump at the injection site for a couple weeks, this medication has really helped me cut back my urge to eat by about 60%.
5Patient Review
2/16/2018
Bydureon for Additional Medication for Diabetes Type 2
I've only been taking this medication for a short while, but I can already tell it's making a difference. My appetite is better and my blood sugar isn't spiking as much. I still get headaches occasionally, but they might be unrelated to the Bydureon.
5Patient Review
12/15/2017
Bydureon for Type 2 Diabetes Mellitus
I had some mild side effects with this treatment, but overall it was very effective. It's cut my urge to eat by about 60%, which has been a huge help for me.
3Patient Review
6/24/2018
Bydureon for Additional Medication for Diabetes Type 2
I experienced some heart palpitations and an increase in my heartbeat. I also had explosive bowel movements, sore throat, decreased appetite, and weight loss. However, my glucose readings were way down and more consistent.
3Patient Review
10/29/2019
Bydureon for Type 2 Diabetes Mellitus
This is generally working well for me, but I have developed a rash and some bruising on my stomach. Additionally, I've lost my appetite and am feeling very full all the time.
3Patient Review
10/29/2019
Bydureon for Type 2 Diabetes Mellitus
This treatment is effective, but I have experienced some stomach trouble as a result. I get rashes and bruises easily, and I haven't been feeling very hungry lately.
3Patient Review
6/24/2018
Bydureon for Additional Medication for Diabetes Type 2
This treatment has helped my glucose readings stay consistent, but I've also experienced some less desirable side effects like an increased heart rate, palpitations, explosive bowel movements, and a sore throat.
2.7Patient Review
3/17/2018
Bydureon for Additional Medication for Diabetes Type 2
I've been using this drug for over a year now, and I have yet to see any improvement. If anything, the lumps have gotten worse, and I always feel nauseous before and after treatment. Additionally, about one out of every eight syringes is unreliable. If you are prescribed this medication, plan on spending an hour for treatment. Slow down for half an hour after injection before moving around; otherwise, the needle (which is quite large) will leak.
2.7Patient Review
3/17/2018
Bydureon for Additional Medication for Diabetes Type 2
I've been using this for over a year now and, unfortunately, have not seen much improvement. I still get lumps and nausea both before and after treatment, about one out of every eight syringes is unreliable, and the injection site often leaks afterwards. On the plus side, it only takes an hour to do the whole process.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bydureon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Bydureon a insulin?

"No, Bydureon does not contain insulin, but it does stimulate the body to produce more insulin. Is Bydureon used as a weight loss drug? No. Bydureon is not marketed as a weight loss drug, although weight loss is a common side effect."

Answered by AI

Is Ozempic better than Bydureon?

"Ozempic caused patients to have lower A1c levels and lose more weight than patients who took Bydureon or Trulicity in clinical trials. Mar 7, 2018"

Answered by AI

Is Trulicity and Bydureon the same?

"The drugs Bydureon and Trulicity both work to improve blood sugar levels in people with type 2 diabetes by mimicking the peptide hormone GLP-1."

Answered by AI

Why is Bydureon being discontinued?

"AstraZeneca announced that it will be discontinuing Bydureon (exenatide) Pen as of March 2021 due to business reasons. The discontinuation is not due to safety or efficacy issues, product quality or manufacturing concerns. Bydureon BCise® (exenatide) Pen will continue to be available."

Answered by AI

Is Bydureon an insulin?

"No, Bydureon is not the same as insulin, but it does cause the body to release more insulin. Is Bydureon used as a weight loss drug? No, it is not approved for that purpose, even though many people who use it do lose weight."

Answered by AI

Is Ozempic and Bydureon the same?

"The side effects of Bydureon include headache, itching, indigestion, and a small bump at the injection site. These side effects are different from those of Ozempic. Both Ozempic and Bydureon may interact with insulin secretagogues or insulin, as well as other oral medications taken at the same time. In addition, Bydureon may interact with warfarin."

Answered by AI

What type of insulin is Bydureon?

"Type 2 diabetes Mellitus is a condition in which the body does not provide sufficient insulin.

Bydureon is a prescription medication used to manage the symptoms of Type 2 Diabetes Mellitus. It may be used alone or with other medications. Bydureon is part of a class of drugs called Antidiabetics, Glucagon-like Peptide-1 Agonists. Type 2 Diabetes Mellitus is characterized by the body not producing enough insulin."

Answered by AI

Why was Bydureon discontinued?

"- OptumRx® today announced that it will no longer cover AstraZeneca’s Bydureon® (exenatide) Pen as of March 14, 2021, due to the drug maker’s discontinuation of the product. — This decision is not related to any safety or efficacy issues, product quality or manufacturing concerns. OptumRx will instead cover Bydureon BCise® (exenatide), which is also manufactured by AstraZeneca.

As of March 2021, AstraZeneca will be discontinuing its Bydureon Pen due to business reasons. This decision is not related to any safety or efficacy issues, product quality or manufacturing concerns. Bydureon BCise will continue to be available. As of March 14, 2021, OptumRx will no longer cover AstraZeneca's Bydureon Pen. Instead, OptumRx will cover Bydureon BCise, which is also manufactured by AstraZeneca."

Answered by AI

Clinical Trials for Bydureon

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Bydureon clinical trials? We made a collection of clinical trials featuring Bydureon, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Have you considered Bydureon clinical trials? We made a collection of clinical trials featuring Bydureon, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Bydureon clinical trials? We made a collection of clinical trials featuring Bydureon, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security